In an open‐label Phase 1 clinical trial, a single IV administration of RP‐A501 (AAV9.LAMP2B) was shown to effectively deliver and transduce cardiomyocytes in patients afflicted with DD—an X‐linked monogenic cardiomyopathy attributed to mutations in the LAMP2 gene. Here, LAMP2 is linked to cardiomyopathy.